Inhibition of cardiac CaMKII to cure heart failure: step by step towards translation? by unknown
INVITED EDITORIAL
Inhibition of cardiac CaMKII to cure heart failure:
step by step towards translation?
Friederike Cuello1,2 • Kristina Lorenz3,4,5
Received: 12 September 2016 / Accepted: 12 September 2016 / Published online: 28 September 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
During the past decade, calcium/calmodulin-dependent
protein kinase II (CaMKII) has emerged as a central culprit
in the development of cardiac arrhythmia and heart failure.
This has been supported by a plethora of studies using
transgenic mouse models and pharmacological CaMKII
inhibitors and peptides. However, the final proof that
CaMKII inhibition improves dysfunction of a failing heart
is still pending. In this issue, Kreusser et al. [19] demon-
strated that knockdown of the two key cardiac CaMKII
isoforms after the onset of hemodynamic stress succeeds to
reverse maladaptive cardiac remodeling processes. Their
study is an important step in translating CaMKII inhibition
from bench to bedside for heart failure therapy.
CaMKII is a multifunctional protein kinase that plays a
pivotal role in cardiac (patho) physiology [27, 40]. It rep-
resents a nodal point in the regulation of intracellular Ca2?
handling, ion channels and gene transcription. As the
description ‘‘multifunctional’’ and ‘‘nodal point’’ implies,
this kinase is intertwined into a complex cellular signaling
network and thus tricky to manipulate therapeutically:
CaMKII activity is regulated by posttranslational modifi-
cations that allow maintenance of kinase activity indepen-
dently of Ca2?/calmodulin-binding. Amongst those
autophosphorylation [16, 26, 45], oxidation [2, 7, 13, 32,
45], O-linked N-acetylglucosamination [9] and S-nitrosy-
lation [8, 12] have been described to date. CaMKII has
various cellular targets in Ca2? homeostasis some of which
are the ryanodine receptor [26, 34, 39, 41], phospholamban
[5, 18] and cardiac myosin-binding protein C [37]. Fur-
thermore, CaMKII impacts on L-type Ca2? channel (LTCC)
currents and LTCC expression [40], on expression of the
Na?/Ca2? exchanger [10, 23] and the sarcoplasmic reticu-
lum Ca2? ATPase 2a (SERCA2a) [5, 23, 42] as well as on
gene transcription via the regulation of calcineurin and class
II histone deacetylase isoforms [3, 24]. CaMKII is ubiqui-
tously expressed, with a and b as predominant isoforms in
the brain, where they are important for neuronal function
and cognitive memory. CaMKIIc and d are the key isoforms
expressed in the heart. Particular attention has been paid to
two CaMKIId splice variants in the heart, CaMKIIdB and
CaMKIIdC. CaMKIIdB has an 11 amino acid nuclear
localization sequence that is absent in CaMKIIdC. Studies
performed in splice-variant-specific knockout mouse mod-
els have attributed a protective functional role to CaMKIIdB.
Thus, cellular localization seems to participate in CaMKII
isoform-specific pathophysiological roles [4, 5, 28, 44].
Despite of the physiological importance of CaMKII, for
e.g,. excitation–contraction coupling, isoproterenol-induced
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heart rate adaptation, cognitive memory and neural plas-
ticity functions, inhibition of CaMKII as a therapeutic
strategy in different forms of cardiac disease increasingly
solidifies. Cardiac expression and activity of CaMKII have
been shown to be increased in cardiac disease and more
importantly also augments the incidence of cardiac disease,
particularly arrhythmia, atrial fibrillation and progressive
cardiac remodeling [6, 15, 17, 21, 27, 29, 42, 43]. Proof-of-
concept studies in mice and isolated human cardiac myo-
cytes have successfully demonstrated the benefit of CaM-
KIId and CaMKIIc inhibition in several pathological
cardiac conditions. However, translation of these con-
vincing preclinical ‘‘prevention’’ studies into therapeutic
strategies or even a preclinical ‘‘therapy/rescue’’ study
seems rather challenging.
Difficult hurdles that have to be envisaged to selectively
target disease-specific kinase functions [22, 38] to ulti-
mately achieve clinical translatability are the design of (1)
appropriate cardiac-specific gene therapy approaches for
the expression of inhibitory peptides, proteins or knock-
down-vectors or (2) isoform-specific, orally administrable,
non-CNS penetrating small compound inhibitors. The
peptides and compounds that have been developed thus far
have been shown to exert off-target effects, which include
the inhibition of potassium channels (KN-93; [14]),
blockade of anchoring proteins and substrates (CaMKIIN
and CaMKIINtides; [25, 30]) and in case of ATP-com-
petitive compounds the inhibition of other kinases (SMP-
114; [30]), or they are orally not bioavailable [30].
Pharmacological CaMKII inhibitors as well as the
transgenic mouse models have been extremely valuable for
dissecting the functional roles of CaMKII in cells and
in vivo, but they remain experimental tools (reviewed in
[29, 30, 42]). And, the question, whether CaMKII inhibi-
tion—in an ideal ‘‘off-target free’’ setting—has the poten-
tial to ameliorate cardiac remodeling and cardiac function
after the onset of heart failure, is still unanswered. With the
tools available, this question was not yet appropriately
addressable. Kreusser et al. [19] have now developed
genetic mouse models with inducible CaMKIId and c
knockdown to address exactly this issue: ‘‘Is CaMKII
inhibition able and sufficient to rescue a failing heart?’’
And the answer from this mouse study is ‘‘Yes’’! This is the
first time that CaMKII inhibition has been tested in a
‘‘therapy/rescue’’ situation.
In their study, the authors use mouse models that are
based on a cardiac-specific conditional knockdown of
CaMKIId and c by tamoxifen or by Cre-recombinase
overexpression via adeno-associated viral vectors. In both
approaches, the development of interstitial fibrosis and
contractile defects in response to chronic left ventricular
pressure overload (induced by transverse aortic constric-
tion) was decelerated and even slightly reversed. This study
shows convincingly that inhibition of cardiac CaMKII
expression is a promising goal for the improvement of
chronic heart failure therapy. Thus, the effort has to be
taken and to be enforced to realistically name CaMKII a
clinically relevant target.
However, it will still be a long and arduous way to
implement clinical CaMKII inhibition for heart failure
therapy. Due to the high homology between existing CaM-
KII isoforms and their physiological roles, CaMKII targeting
strategies have to take cardiac and isoform specificity into
account. In this context, the establishment of a gene therapy
approach seems ‘‘easier’’ than the development of pharma-
cological inhibitors. Also, gene therapy studies in large
animals or even patients have already been tested for
S100A1, SERCA2a and adenylyl cyclase 6
[1, 11, 20, 31, 33, 35, 36]. SERCA2a gene therapy has
already reached clinical phase IIb studies, but then failed due
to insufficient delivery of viral particles to the heart. Nev-
ertheless, these studies delivered proof of the general con-
cept, and have at the same time revealed the difficulties that
still need to be overcome. For the development of small
pharmacological compounds, even more challenges have to
be faced: As mentioned before, the CaMKII family com-
prises highly homologous isoforms and splice variants,
which makes selective pharmacological targeting of a
specific isoform or splice variant rather impossible. At this
point, the manipulation of certain downstream targets of
CaMKII comes into play. Thus far, however, it is not clear,
which of the targets has the major impact on cardiac disease
progression or if there are even targets of different impor-
tance in different cardiac diseases. It will be a major effort to
dissect the impact of the CaMKII-mediated molecular
effects in different disease scenarios to really be able to
predict the therapeutic benefit of target specific CaMKII
inhibition. To promote the design of an appropriate phar-
macological compound, we will certainly have to disentan-
gle physiological from the pathological CaMKII functions.
With their study Kreusser et al. [19] have clearly demon-
strated that CaMKII inhibition is the right avenue to tread
for significant benefit in heart failure therapy in the future.
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